SynthesisFrontiers in endocrinology2022
Diagnostic performance of C-TIRADS in malignancy risk stratification of thyroid nodules: A systematic review and meta-analysis.
Synthesis in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Development and validation of a predictive model for thyroid nodule malignancy risk based on intralesional and perilesional ultrasound radiomic features.Gland surgery · 2026Article
- Development and clinical validation of an artificial intelligence based model for thyroid nodule malignancy risk assessment using C-TIRADS guidelines.Frontiers in medicine · 2026Article
- Comparative diagnostic performance of C-TIRADS versus Kwak TI-RADS for thyroid nodules: implications for fine-needle aspiration biopsy referral.Frontiers in endocrinology · 2026Article
- The Value of a Predictive Model Based on Multimodal Ultrasound Imaging Biomarkers Combined with Clinical Features in the Diagnosis of Thyroid Nodules.Current medical imaging · 2026Article
- Application of fine-needle aspiration biopsy combined with multi-gene testing in the differential diagnosis of benign and malignant C-TIRADS 4 thyroid nodules.Frontiers in medicine · 2026Article
- Assessing agreement with a single-center expert consensus: artificial intelligence-assisted teleultrasound for thyroid nodules categorized as C-TIRADS 4A or higher.Frontiers in endocrinology · 2026Article
- The value of C-TIRADS combined with multidimensional indicators in the diagnosis of papillary thyroid carcinoma.Gland surgery · 2025Article
- Contrast-enhanced ultrasound combined with shear wave elastography in the diagnosis of C-TIRADS category 4 thyroid nodules.Quantitative imaging in medicine and surgery · 2025Article
- Development and validation of a nomogram based on conventional and contrast-enhanced ultrasound for differentiating malignant from benign thyroid nodules.Quantitative imaging in medicine and surgery · 2025Article
- Additional diagnostic value of ratio indices of quantitative contrast-enhanced ultrasound parameters in small solid C-TIRADS 4 thyroid nodules.Frontiers in oncology · 2025Article
- A nomogram for predicting the nature of thyroid adenomatoid nodules on ultrasound: a dual-center study.Frontiers in oncology · 2025Article
- The predictive value of the ultrasound grayscale ratio for identifying malignant thyroid nodules.Frontiers in endocrinology · 2025Article
- The Impact of Echogenicity Grading on the Diagnostic Performance of C-TIRADS.International journal of general medicine · 2025Article
- Combined model integrating clinical, radiomics, BRAFGland surgery · 2024Article
- The Horizon of Thyroid Imaging Reporting and Data System in the Diagnostic Performance of Thyroid Nodules: Clinical Application and Future Perspectives.TouchREVIEWS in endocrinology · 2024Review
- Thyroid collision tumour with pulmonary metastases treated effectively with nedaplatin and paclitaxel chemotherapy: A case report.The Journal of international medical research · 2023Article
- Comparison of the C-TIRADS, ACR-TIRADS, and ATA guidelines in malignancy risk stratification of thyroid nodules.Quantitative imaging in medicine and surgery · 2023Article
- Comparison of Diagnostic Values of ACR TI-RADS versus C-TIRADS Scoring and Classification Systems for the Elderly Thyroid Cancers.International journal of general medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chinese thyroid imaging reports and data systems (C-TIRADS) is a novel malignancy risk stratification used for thyroid nodule diagnosis and guiding thyroid fine needle aspiration (FNA). In this review, we aim to assess the performance of C-TIRADS in malignancy risk stratification of thyroid nodules. Methods: PubMed, Medline, Web of Science, Embase, CNKI, and Wanfang databases were searched until 1 April 2022. Original articles reporting data about C-TIRADS and setting FNA or histology as reference standards were included. C-TIRADS 4A, 4B, and 4C were set as thresholds, respectively, to obtain pooled sensitivity, specificity, positive likelihood ratio (LR+), negative likelihood ratio (LR-), diagnostic odds ratio (DOR), and the area under the curve (AUC). Integrated nested Laplace approximation was used for Bayesian bivariate meta-analysis of diagnostic tests. Results: Sixteen studies were included, evaluating 11,506 thyroid nodules. The rate of malignancy in each risk classification is comparable with that in C-TIRADS. C-TIRADS 4B appeared to have better diagnostic performance than C-TIRADS 4A and 4C. The pooled sensitivity, specificity, LR+, LR-, and DOR of C-TI-RADS 4B were 0.94 (95% CI: 0.89-0.97), 0.70 (95% CI: 0.60-0.79), 3.20 (95% CI: 2.28-4.39), 0.09 (95% CI: 0.05-0.15), and 33.71 (95% CI: 25.51-42.40), respectively. The area under the summary ROC curve was 0.94 (95% CI: 0.90-0.96). Conclusion: C-TIRADS performed well in malignancy risk stratification of thyroid nodules. C-TIRADS 4B showed strong evidence of detecting malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.